Long Term Follow-Up Study of the Safety and Exploratory Efficacy of Pneumostem in Premature Infants With Bronchopulmonary Dysplasia
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 10 Apr 2019
Price : $35 *
At a glance
- Drugs Mesenchymal stem cell therapy (Primary)
- Indications Bronchopulmonary dysplasia
- Focus Adverse reactions
- Sponsors Samsung Medical Center
- 07 Apr 2019 Planned End Date changed from 1 Sep 2017 to 1 Sep 2026.
- 07 Apr 2019 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2025.
- 19 May 2015 Planned End Date changed from 1 Dec 2013 to 1 Sep 2017 as reported by ClinicalTrials.gov record.